Solara Active Pharma [SOLARAPP] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Solara Active Pharma Sciences Ltd. wins in 6 metrics, Sun Pharmaceutical Industries Ltd. wins in 13 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Solara Active Pharma Sciences Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 2,428.57 | 36.73 | Sun Pharmaceutical Industries Ltd. |
| Price-to-Book Ratio | 1.25 | 5.15 | Solara Active Pharma Sciences Ltd. |
| Debt-to-Equity Ratio | 72.58 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | -24.26 | 3.59 | Sun Pharmaceutical Industries Ltd. |
| EV/EBITDA | 10.57 | 23.61 | Solara Active Pharma Sciences Ltd. |
| Profit Margin (TTM) | 0.04% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 7.72% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | 7.72% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| Return on Equity | 0.05% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | 2.92% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $1.73B | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | 22.59% | 7.25% | Solara Active Pharma Sciences Ltd. |
| Price-to-Sales Ratio (TTM) | 1.65 | 7.05 | Solara Active Pharma Sciences Ltd. |
| Enterprise Value | $21.80B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 1.70 | 6.66 | Solara Active Pharma Sciences Ltd. |
| Gross Profit Margin (TTM) | 54.11% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $333 | $237 | Solara Active Pharma Sciences Ltd. |
| Earnings per Share (Diluted) | $0.14 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | 1.12 | 0.11 | Sun Pharmaceutical Industries Ltd. |
Solara Active Pharma Sciences Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences Ltd. | -0.31% | -3.50% | -4.34% | 63.68% | 63.68% | 63.68% |
| Sun Pharmaceutical Industries Ltd. | -0.47% | -3.03% | -1.92% | 2.17% | -1.01% | 3.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences Ltd. | 22.59% | 90.07% | 90.07% | 90.07% | 90.07% | 90.07% |
| Sun Pharmaceutical Industries Ltd. | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
Performance & Financial Health Analysis: Solara Active Pharma Sciences Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | SOLARAPP | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹21.12B | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 578 | 3,903,142 |
| 90 Day Avg. Volume | 614 | 3,253,866 |
| Last Close | ₹446.85 | ₹1,780.10 |
| 52 Week Range | ₹215.55 - ₹560.85 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -20.33% | -7.12% |
| All-Time High | ₹560.85 (Dec 09, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -20.33% | -9.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.14% |
| Quarterly Earnings Growth | -0.12% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.19% |
| Operating Margin (TTM) | 0.08% | 0.26% |
| Return on Equity (TTM) | 0.00% | 0.15% |
| Debt to Equity (MRQ) | 72.58 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹271.86 | ₹324.46 |
| Cash per Share (MRQ) | ₹1.02 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹2.13B | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹-173,124,992 | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | N/A | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Solara Active Pharma Sciences Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | SOLARAPP (Aug 03, 2025) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 2,428.57 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | -24.26 | 3.59 |
| Price to Sales (TTM) | 1.65 | 7.05 |
| Price to Book (MRQ) | 1.25 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹21.12B | ₹3.88T |
| Enterprise Value | ₹21.80B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.70 | 6.66 |
| Enterprise to EBITDA | 10.57 | 23.61 |
| Risk & Other Metrics | ||
| Beta | 1.12 | 0.11 |
| Book Value per Share (MRQ) | ₹271.86 | ₹324.46 |
Financial Statements Comparison: Solara Active Pharma Sciences Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | SOLARAPP (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 12.84B | 520.41B |
| Cost of Goods Sold | 6.26B | 121.98B |
| COGS % of Revenue | 48.8% | 23.4% |
| Gross Profit | 6.57B | 398.44B |
| Gross Margin | 51.2% | 76.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 1.07B | 125.81B |
| Operating Margin | 8.3% | 24.2% |
| EBITDA | 2.15B | 167.25B |
| EBITDA Margin | 16.7% | 32.1% |
| Pre-Tax Income | 5.40M | 137.52B |
| Pre-Tax Income % of Revenue | 0.0% | 26.4% |
| Income Tax | 0 | 27.72B |
| Income Tax % of Revenue | 0.0% | 5.3% |
| Net Income (Profit) | 5.40M | 109.65B |
| Profit Margin | 0.0% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | SOLARAPP (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 39.50M | 102.69B |
| Total Current Assets | 7.29B | 526.24B |
| Total Current Assets % of Revenue | 56.8% | 101.1% |
| Total Current Liabilities | 9.44B | 181.94B |
| Total Current Liabilities % of Revenue | 73.5% | 35.0% |
| Long-Term Debt | 1.32B | 3.58B |
| Long-Term Debt % of Revenue | 10.3% | 0.7% |
| Total Shareholders Equity | 10.97B | 724.86B |
| Retained Earnings | N/A | 578.62B |
| Retained Earnings % of Revenue | 0.0% | 111.2% |
| Property, Plant & Equipment | 7.96B | 100.36B |
Cash Flow Statement Comparison
| Metric | SOLARAPP (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | 1.74B | 110.84B |
| Operating Cash Flow % of Revenue | 13.6% | 21.3% |
| Capital Expenditures | 3.80M | -20.68B |
| Free Cash Flow | 1.73B | 119.44B |
| FCF Margin | 13.5% | 23.0% |
| Debt Repayment | -1.11B | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | SOLARAPP | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 48.05M | 2.40B |
| Float Shares | 27.66M | 1.07B |
| % Held by Insiders | 0.00% | 55.62% |
| % Held by Institutions | 4.46% | 28.69% |
| % Held by Public | 95.54% | 15.69% |
Dividend Analysis & Yield Comparison: Solara Active Pharma Sciences Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | SOLARAPP | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | N/A | ₹17.33 |
| 3-Year Avg Dividend Yield | N/A | 0.51% |
| 3-Year Total Dividends | N/A | ₹52.00 |
| Ex-Dividend Date | N/A | Feb 05, 2026 |